Summary

Original source:
http://www.earthtimes.org/articles/show/1346.html

Details

• J&J submits risk report of Reminyl - Stock value of Johnson & Johnson Pharmaceutical Company has fallen down from 64 cents to 61.85 as the company unveiled the risks carried by its drug Reminyl.
• The company has submitted the study report to the FDA.
• Reminyl is a cholinesterase inhibitor that is extracted from daffodil bulbs.
• It boosts the levels of acetylcholine, a chemical that transmits nerve signals in the brain.
• Johnson & Johnson earns about US$200 million a year from the drug.
• The study conducted by J&J attempted to check whether the drug could be used for treating cognitive impairment that leads to memory loss and may develop into Alzheimer's disease.
• Observations made by the researchers in the last two years during the course of the study revealed that patients taking Reminyl showed higher death rate than those on placebo.
• 15 patients taking Reminyl died compared with five taking the placebo.
• Although the drug is approved in 69 countries as an effective treatment on mild to moderate conditions of Alzheimer, it is not yet approved for treating cognitive impairment.
• The company has said that they are not planning to make any application for this use of the drug.
• Carol Goodrich spokeswoman for the company said "the health authorities that are reviewing this data ...
• are still supporting its use for the approved indication, which is mild to moderate Alzheimer's disease."
• Health Canada's spokeswoman Carole Saindon, said data is not yet completely analyzed and they would keep the public informed as new developments surface.
• She said that, "it's very important that patients don't stop taking the medication without consulting their doctor first."

Related Articles

Popular Topics: Reminyl, Johnson & Johnson, Alzheimer's, Diabetes, Breast cancer, Prostate cancer, Heart disease, Depression, High cholesterol, Osteoporosis, Vaccines, Autism, ADHD, Infertility, Weight loss, Cancer, Alzheimer's, Trans fats, Acrylamides, Fluoride, Mercury	Take Action: Support NaturalNews.com Email this article to a friend Share this article on: NewsVine | digg | del.icio.us Permalink to this article: http://www.NaturalNews.com/004288_Reminyl_Johnson_&_Johnson_Alzheimers.html Reprinting this article: Non-commercial use OK, cite NaturalNews.com with clickable link. <a href = "http://www.NaturalNews.com/004288_Reminyl_Johnson_&_Johnson_Alzheimers.html">Johnson & Johnson's stock falls as bad news about Reminyl hits the street</a>
Receive our Natural Health Newsletter for FREE Subscribe now (it's free!) to win. We randomly choose a subscriber each month to send $100 in eco-home products or a RealGoods.com gift certificate (our choice). Plus, you'll receive FREE news, articles and action alerts from NaturalNews.com editors and join over 800,000 monthly readers who report extraordinary health improvements after becoming a subscriber! Receive breaking news alerts on natural health solutions, renewable energy, the environment, global warming and more. Receive a free instant download of our $29 Secret Sources guide that reveals top sources for little-known health and diet solutions.	Your Email Address: Free Subscription Code: Enter the numbers you see: 100% free of charge. Unsubscribe anytime. Absolutely no spam. We respect your email privacy.
Recommended Special Report: Seven Words that can Change the World by Joseph R. Simonetta Read this special report now... "Seven Words That Can Change the World reveals the astonishing, simple truths that have the power to forever transform our world for the better while freeing our minds from the enslavement of limiting beliefs. This is not a text for the simple-minded; it is a guiding philosophy for the mindful, intelligent few who are wise enough to seek out -- and recognize -- the higher simplicities of truly purposeful living." - Mike Adams, the Health Ranger, editor of NaturalNews.com	More on NaturalNews.com: • Streaming Health Ranger Videos • CounterThink Cartoons • FREE Special Reports • Podcasts